Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Non-Current Assets (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Non-Current Assets for 9 consecutive years, with $244.2 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 52.09% to $244.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, down 54.25% year-over-year, with the annual reading at $244.2 million for FY2025, 52.09% down from the prior year.
  • Non-Current Assets for Q4 2025 was $244.2 million at Denali Therapeutics, up from $173.0 million in the prior quarter.
  • The five-year high for Non-Current Assets was $607.5 million in Q1 2024, with the low at $81.7 million in Q2 2023.
  • Average Non-Current Assets over 5 years is $277.0 million, with a median of $204.7 million recorded in 2022.
  • The sharpest move saw Non-Current Assets tumbled 82.66% in 2022, then surged 621.67% in 2024.
  • Over 5 years, Non-Current Assets stood at $506.9 million in 2021, then crashed by 82.66% to $87.9 million in 2022, then rose by 2.11% to $89.8 million in 2023, then soared by 467.77% to $509.7 million in 2024, then crashed by 52.09% to $244.2 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $244.2 million, $173.0 million, and $231.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.